Rise Advisors’s Bionano Genomics BNGO Stock Holding History

Rise Advisors’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-106	Closed	-$296	–	1559
2025 Q1	$296	Buy	+106	New	+$694	﹤0.01%	1424

Other funds holding BNGO

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SSG

Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return

Rise Advisors's BNGO Position: Q2 2025 in Review

Rise Advisors sold out of Bionano Genomics (BNGO) in Q2 2025, closing a stake of 106 shares — an estimated $296 sold.

Rise Advisors first reported a position in BNGO in Q1 2025 and held it in 1 quarter. The position peaked at $296 in Q1 2025. 29 funds tracked by Wall St. Rank hold BNGO as of Q2 2025.

Rise Advisors reported no remaining Bionano Genomics position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 106 Bionano Genomics shares in Q2 2025, an estimated $296.
Rise Advisors first reported a position in Bionano Genomics in Q1 2025 and held it in 1 quarter.
Rise Advisors's Bionano Genomics position peaked at $296 in Q1 2025.
29 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.